Johnson & Johnson <a href="https://www.reuters.com/markets/companies/JNJ.N" target="_blank">(JNJ.N)</a> said on Thursday the U.S. Food and Drug Administration had approved its antibody-based therapy for patients with a difficult-to-treat type of blood cancer.